Prostate Radiation Therapy Does Not Affect BCG Efficacy in NMIBC
Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.
Diagnosis & Disease Information
High-Risk NMIBC Effectively Treated With a BCG Alternative
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
Novel Immunotherapy Plus BCG Effective for Unresponsive Bladder Cancer
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
Trimodal Therapy Appears Equivalent to Radical Cystectomy for Select MIBC Patients
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
Neoadjuvant Chemotherapy Deemed New Standard Care in Urothelial Carcinoma
The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.
Niraparib Maintenance Failed to Improve Outcomes in Advanced Urothelial Carcinoma
The median progression-free survival was similar between the treatment arms.
AAP Does Not Increase Bone Loss in Metastatic Castration-Sensitive Prostate Cancer
Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.
Prostate Cancer Screening and Treatment Patterns Differ Across Countries
Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.
Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate Cancer
Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.
- Loading...
Loading...
Next post in ASCO GU 2022
Loading... 
Loading...